Floatz logo

DEXAMETHASONE

Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type cohort.

Asset / SponsorPhaseRating
Ibrutinib
National Cancer Institute (NCI)
Phase 2CCC
Venetoclax
National Cancer Institute (NCI)
Phase 2CCC
Obinutuzumab
National Cancer Institute (NCI)
Phase 2CCC
Golcadomide
Mayo Clinic
Phase 2CCC
cc-5013
National Cancer Institute (NCI)
Phase 2CCC

View all 9 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →